APA (7th ed.) Citation

A, J., NR, F., A, W. H., MS, B., SJ, W., EJ, A., . . . AP, F. (2026). A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer. American journal of clinical oncology, 49(5), 238. https://doi.org/10.1097/COC.0000000000001263

Chicago Style (17th ed.) Citation

A, Jatoi, Foster NR, Wahner Hendrickson A, Block MS, Weroha SJ, Asmus EJ, Murray NR, and Fields AP. "A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer." American Journal of Clinical Oncology 49, no. 5 (2026): 238. https://doi.org/10.1097/COC.0000000000001263.

MLA (9th ed.) Citation

A, Jatoi, et al. "A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer." American Journal of Clinical Oncology, vol. 49, no. 5, 2026, p. 238, https://doi.org/10.1097/COC.0000000000001263.